Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 16/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833756 | 0.88 | GHSR (0.39) | GHSRNR1H2 | |
| SCHEMBL17833755 | 0.85 | MEN1 (0.41) | GHSRNR1H2ESR2 | |
| SCHEMBL3607650 | 0.81 | GHSR (0.44) | GHSRNR1H2ESR2ACE | |
| SCHEMBL1202033 | 0.79 | SMN1; SMN2 (0.53) | — | |
| SCHEMBL25895785 | 0.79 | GHSR (0.48) | GHSRNR1H2 | |
| SCHEMBL17833752 | 0.79 | GHSR (0.41) | GHSR | |
| SCHEMBL3069653 | 0.77 | ESR2 (0.54) | GHSRESR2 | |
| Ethane SCHEMBL29233312 | 0.77 | ESR2 (0.54) | GHSRESR2 | |
| SCHEMBL7511979 | 0.77 | ESR2 (0.54) | GHSRNR1H2ESR2ACE | |
| SCHEMBL8224318 | 0.76 | GHSR (0.54) | GHSRESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9518022-B2 | Anti-HIV compounds | PROSETTA ANTIVIRAL INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | MAVS, SARS1, NFATC1 | GHSR 4832/4885NR1H2 837/4885ESR2 4497/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | GHSR 4858/4885NR1H2 2067/4885ESR2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.